Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC) von Gradishar, W, Krasnojon, D, Cheporov, S, Makhson, A, Manikhas, G, Clawson, A, Bhar, P

Volltext

2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metast... von Gradishar, W.J, Krasnojon, D, Cheporov, S, Makhson, A, Georgy, M, Clawson, A, Hawkins, M.J

Volltext

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase... von Gradishar, WJ, Krasnojon, D, Cheporov, S, Makhson, AN, Manikhas, GM, Clawson, A, Bhar, P

Volltext

P5-19-13: A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2 von Gradishar, WJ, Krasnojon, D, Cheporov, S, Makhson, AN, Manikhas, GM, Clawson, A, Bhar, P

Volltext

Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial von Gradishar, W. J., Krasnojon, D., Cheporov, S. V., Makhson, A., Manikhas, G. M., Clawson, A., Bhar, P.

Volltext

Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC) von Vukelja, S. J., O'Shaughnessy, J., Krasnojon, D., Cheporov, S. V., Makhson, A., Manikhas, G., Bhar, P., Gradishar, W.

Volltext

Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC) von Gradishar, W., Krasnojon, D., Cheporov, S., Makhson, A., Manikhas, G., Clawson, A., Hawkins, M. J.

Volltext